Two-thirds of public sector cancers caught late, private sector early
Six years after a state law promised it, residents of Minas Gerais will finally be able to access free genetic screening for hereditary cancer risk through Brazil's public health system beginning in January 2026. The delay was not born of indifference alone, but of a deeper fragility in public oncology infrastructure that had to be rebuilt before the promise could be honored. In a country where the timing of a cancer diagnosis often depends on whether one can afford private care, this program represents a quiet but consequential attempt to rebalance an old inequity.
- A law passed in 2019 went unimplemented for six years while public sector cancer patients continued to receive diagnoses at late, harder-to-treat stages at twice the rate of those in private care.
- The gap between legislation and action was not merely bureaucratic — outdated equipment producing false results, underpaid technicians, and absent laboratory infrastructure meant the foundation itself had to be rebuilt before the promise could be kept.
- Advocacy groups like Pérolas Negras maintained sustained pressure on the state government, ensuring the law did not quietly expire into irrelevance.
- Starting January 2026, approximately 2,000 people per year will receive BRCA1/BRCA2 tests at no cost, with samples processed at UFMG and the state absorbing the roughly 1,100 reais cost per test.
- The program's real test lies ahead: whether funding holds, whether health workers are adequately trained, and whether the people who most need this screening will ever learn it exists.
Beginning in January 2026, residents of Minas Gerais will be able to visit a public health clinic and request a blood or saliva test for BRCA1 and BRCA2 mutations — genetic markers that significantly elevate the risk of breast and ovarian cancer. The path to this moment was long. A state law mandating the screening passed in 2019, then sat dormant for six years while the gap it was meant to close continued to widen.
That gap is stark. In Brazil's public health system, two-thirds of breast cancer cases are diagnosed only after the disease has advanced, requiring aggressive treatment. In private clinics, the ratio inverts — two-thirds of diagnoses come early, when outcomes are better and interventions less severe. Genetic screening that identifies elevated risk before cancer develops could begin to change that calculus for public sector patients.
Health Secretary Fábio Baccheretti acknowledged the delay, attributing it to the fragility of the public oncology infrastructure itself. Before genetic testing could be offered, the state had to raise pay for mammography technicians, distribute funding for new equipment, and replace machines old enough to produce unreliable results. The foundation, he argued, had to come first.
Advocacy organizations pushed throughout those six years to ensure the law was not forgotten. Maria Luiza, president of the Pérolas Negras association, noted the sustained pressure these groups applied to move implementation forward. Roughly 2,000 tests will be offered annually, processed at the Federal University of Minas Gerais, with the state covering the full cost of approximately 1,100 reais each.
Training for public health workers — doctors, nurses, and laboratory staff — will accompany the rollout, guided by UFMG. The infrastructure is taking shape. What remains uncertain is whether the commitment will endure: whether funding continues, whether clinics absorb the volume, and whether the people who most need this test will know to ask for it.
Starting in January, people in Minas Gerais will be able to walk into a public health clinic and get a blood or saliva test that could tell them whether they carry mutations in the BRCA1 or BRCA2 genes—the genetic markers that sharply elevate the risk of breast and ovarian cancer. The test itself is straightforward. The wait to get it has been anything but.
A state law mandating this screening passed in 2019. For six years, it sat unimplemented. Now, finally, the public health system is moving forward. Starting next year, roughly two thousand people annually will be able to access the test through the SUS, Brazil's unified health system. Samples will be collected at local clinics and sent to the Federal University of Minas Gerais for laboratory analysis. The state is footing the bill—each test costs about 1,100 reais—and absorbing the full expense.
The delay matters because of what happens when cancer is caught late versus early. In the public sector, two-thirds of breast cancers are discovered only after they've progressed significantly, forcing patients into aggressive treatment regimens: surgery, radiation, chemotherapy. The toll is not just medical but financial and personal. In private clinics, the pattern inverts. Two-thirds of diagnoses come early, when intervention is less invasive and outcomes tend to be better. A genetic test that identifies risk before cancer develops could narrow that gap.
A positive result does not mean someone will develop cancer. It means the risk is elevated and warrants close monitoring. Results can also come back negative or inconclusive. But for people with family histories of the disease, or those whose genetic profile suggests inherited risk, the test offers clarity that the public system has never before provided.
Fábio Baccheretti, the state's health secretary, acknowledged the long lag. The reason, he said, was the weakness of the public oncology infrastructure itself. Before rolling out genetic testing, the state had to rebuild the foundation. It raised pay for mammography and biopsy technicians. In 2023, it distributed funding for new mammography machines. Some of the equipment in public oncology hospitals was outdated enough to produce false results. That had to change first.
Maria Luiza, president of the Pérolas Negras association—a group that participated in the state commission pushing for implementation—noted that advocacy organizations had pressed hard for the law to actually be enforced. "There was significant pressure from these organizations on the state to make the law happen," she said. Six years is a long time to wait for something already promised.
The rollout will require training. Public health workers—doctors, nurses, lab technicians—will receive instruction from UFMG, including case discussions and clinical guidance. The infrastructure is being built. The commitment, at least on paper, is there. What comes next is execution: whether the state sustains funding, whether clinics can handle the volume, whether people who need the test actually know it exists and can access it.
Notable Quotes
There was significant pressure from these organizations on the state to make the law happen— Maria Luiza, president of Pérolas Negras association
We had to prepare the ground. We raised pay for technicians, distributed funding for new mammography machines, and fixed equipment that was generating false results— Fábio Baccheretti, health secretary of Minas Gerais
The Hearth Conversation Another angle on the story
Why did it take six years to implement a law that was already written?
The health secretary said the public oncology system wasn't ready. The equipment was failing, the staff wasn't paid enough to stay, the whole foundation was shaky. You can't offer a genetic test if you can't trust your lab results.
So this isn't just bureaucratic delay—it's about actual capacity?
Right. They had to upgrade mammography machines, raise technician salaries, get the infrastructure solid enough that a test result would be reliable. It's not an excuse, but it's a reason.
What changes for a person who gets a positive result?
They don't automatically get cancer. But they know they're at high risk, so they can be monitored closely—regular screenings, preventive measures, informed decisions about their own body. It's the difference between waiting for symptoms and watching for them.
And the equity angle—why does that matter here?
In private clinics, two-thirds of breast cancers are caught early. In public clinics, two-thirds are caught late. By then, treatment is much more brutal and expensive. A genetic test could catch risk before cancer even appears, which is the only way to close that gap.
Two thousand tests a year—is that enough?
It's what the state budgeted for. Whether it's enough depends on how many people actually need it and how many know to ask for it. That's the next challenge.